QQQ   263.21 (-1.37%)
AAPL   107.25 (+0.38%)
MSFT   199.58 (-0.40%)
FB   246.94 (-2.21%)
GOOGL   1,421.98 (-2.01%)
AMZN   2,899.91 (-1.86%)
NVDA   490.34 (+0.57%)
TSLA   442.78 (+0.14%)
BABA   271.44 (-0.36%)
CGC   15.64 (-4.40%)
GE   6.26 (-9.01%)
MU   48.77 (-3.88%)
AMD   76.57 (+2.19%)
T   28.36 (-1.97%)
F   6.86 (-5.12%)
ACB   6.34 (-2.91%)
GILD   63.50 (-2.38%)
NFLX   481.27 (+2.41%)
DIS   124.15 (-3.48%)
BAC   24.16 (-4.17%)
BA   156.51 (-2.87%)
QQQ   263.21 (-1.37%)
AAPL   107.25 (+0.38%)
MSFT   199.58 (-0.40%)
FB   246.94 (-2.21%)
GOOGL   1,421.98 (-2.01%)
AMZN   2,899.91 (-1.86%)
NVDA   490.34 (+0.57%)
TSLA   442.78 (+0.14%)
BABA   271.44 (-0.36%)
CGC   15.64 (-4.40%)
GE   6.26 (-9.01%)
MU   48.77 (-3.88%)
AMD   76.57 (+2.19%)
T   28.36 (-1.97%)
F   6.86 (-5.12%)
ACB   6.34 (-2.91%)
GILD   63.50 (-2.38%)
NFLX   481.27 (+2.41%)
DIS   124.15 (-3.48%)
BAC   24.16 (-4.17%)
BA   156.51 (-2.87%)
QQQ   263.21 (-1.37%)
AAPL   107.25 (+0.38%)
MSFT   199.58 (-0.40%)
FB   246.94 (-2.21%)
GOOGL   1,421.98 (-2.01%)
AMZN   2,899.91 (-1.86%)
NVDA   490.34 (+0.57%)
TSLA   442.78 (+0.14%)
BABA   271.44 (-0.36%)
CGC   15.64 (-4.40%)
GE   6.26 (-9.01%)
MU   48.77 (-3.88%)
AMD   76.57 (+2.19%)
T   28.36 (-1.97%)
F   6.86 (-5.12%)
ACB   6.34 (-2.91%)
GILD   63.50 (-2.38%)
NFLX   481.27 (+2.41%)
DIS   124.15 (-3.48%)
BAC   24.16 (-4.17%)
BA   156.51 (-2.87%)
QQQ   263.21 (-1.37%)
AAPL   107.25 (+0.38%)
MSFT   199.58 (-0.40%)
FB   246.94 (-2.21%)
GOOGL   1,421.98 (-2.01%)
AMZN   2,899.91 (-1.86%)
NVDA   490.34 (+0.57%)
TSLA   442.78 (+0.14%)
BABA   271.44 (-0.36%)
CGC   15.64 (-4.40%)
GE   6.26 (-9.01%)
MU   48.77 (-3.88%)
AMD   76.57 (+2.19%)
T   28.36 (-1.97%)
F   6.86 (-5.12%)
ACB   6.34 (-2.91%)
GILD   63.50 (-2.38%)
NFLX   481.27 (+2.41%)
DIS   124.15 (-3.48%)
BAC   24.16 (-4.17%)
BA   156.51 (-2.87%)
Log in
NASDAQ:SPRO

Spero Therapeutics Stock Forecast, Price & News

$9.78
-0.33 (-3.26 %)
(As of 09/21/2020 02:39 PM ET)
Add
Compare
Today's Range
$9.66
Now: $9.78
$9.84
50-Day Range
$8.96
MA: $11.53
$13.37
52-Week Range
$5.25
Now: $9.78
$14.48
Volume3,104 shs
Average Volume192,608 shs
Market Capitalization$206.88 million
P/E RatioN/A
Dividend YieldN/A
Beta1.69
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. Its product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative infections in the hospital; and SPR720, an oral antibiotic for the treatment of pulmonary non-tuberculous mycobacterial disease. Spero Therapeutics, Inc. has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; collaboration agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Read More
Spero Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.57 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SPRO
CUSIPN/A
Phone857-242-1600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$18.15 million
Book Value$3.90 per share

Profitability

Net Income$-60,920,000.00
Net Margins-715.20%

Miscellaneous

Employees57
Market Cap$206.88 million
Next Earnings Date11/2/2020 (Estimated)
OptionableOptionable
$9.78
-0.33 (-3.26 %)
(As of 09/21/2020 02:39 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SPRO News and Ratings via Email

Sign-up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Spero Therapeutics (NASDAQ:SPRO) Frequently Asked Questions

How has Spero Therapeutics' stock price been impacted by COVID-19?

Spero Therapeutics' stock was trading at $7.75 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SPRO shares have increased by 26.2% and is now trading at $9.78.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Spero Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spero Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Spero Therapeutics
.

When is Spero Therapeutics' next earnings date?

Spero Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Spero Therapeutics
.

How were Spero Therapeutics' earnings last quarter?

Spero Therapeutics Inc (NASDAQ:SPRO) announced its quarterly earnings data on Thursday, August, 6th. The company reported ($0.85) EPS for the quarter, beating the Zacks' consensus estimate of ($1.17) by $0.32. The company earned $1.73 million during the quarter, compared to analyst estimates of $2.95 million. Spero Therapeutics had a negative return on equity of 103.39% and a negative net margin of 715.20%.
View Spero Therapeutics' earnings history
.

What price target have analysts set for SPRO?

5 Wall Street analysts have issued 1 year price targets for Spero Therapeutics' stock. Their forecasts range from $20.00 to $28.00. On average, they anticipate Spero Therapeutics' share price to reach $24.33 in the next twelve months. This suggests a possible upside of 148.8% from the stock's current price.
View analysts' price targets for Spero Therapeutics
.

Are investors shorting Spero Therapeutics?

Spero Therapeutics saw a increase in short interest in August. As of August 31st, there was short interest totaling 1,270,000 shares, an increase of 18.7% from the August 15th total of 1,070,000 shares. Based on an average daily trading volume, of 240,900 shares, the days-to-cover ratio is presently 5.3 days. Currently, 8.5% of the company's stock are sold short.
View Spero Therapeutics' Short Interest
.

Who are some of Spero Therapeutics' key competitors?

What other stocks do shareholders of Spero Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spero Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), SCYNEXIS (SCYX), Kadmon (KDMN), Editas Medicine (EDIT), KushCo (KSHB), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX) and Zosano Pharma (ZSAN).

Who are Spero Therapeutics' key executives?

Spero Therapeutics' management team includes the following people:
  • Dr. Ankit Mahadevia M.D., MBA, Co-Founder, CEO, Pres & Director (Age 39, Pay $747.88k)
  • Ms. Cristina Larkin, Chief Operating Officer (Age 50, Pay $552.96k)
  • Dr. David A. Melnick M.D., Chief Medical Officer (Age 68, Pay $545.96k)
  • Mr. Stephen J. DiPalma M.B.A., Interim CFO & Treasurer (Age 61)
  • Dr. Thomas R. Parr Jr., Chief Scientific Officer (Age 66)

When did Spero Therapeutics IPO?

(SPRO) raised $75 million in an IPO on Thursday, November 2nd 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

What is Spero Therapeutics' stock symbol?

Spero Therapeutics trades on the NASDAQ under the ticker symbol "SPRO."

Who are Spero Therapeutics' major shareholders?

Spero Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Artal Group S.A. (2.58%), BVF Inc. IL (2.30%), AWM Investment Company Inc. (1.15%), Jacobs Levy Equity Management Inc. (0.88%), Russell Investments Group Ltd. (0.45%) and Nuveen Asset Management LLC (0.31%).
View institutional ownership trends for Spero Therapeutics
.

Which major investors are selling Spero Therapeutics stock?

SPRO stock was sold by a variety of institutional investors in the last quarter, including AWM Investment Company Inc., BVF Inc. IL, FMR LLC, FMR LLC, Artal Group S.A., UBS Group AG, and Stifel Financial Corp.
View insider buying and selling activity for Spero Therapeutics
.

Which major investors are buying Spero Therapeutics stock?

SPRO stock was bought by a variety of institutional investors in the last quarter, including Jacobs Levy Equity Management Inc., Russell Investments Group Ltd., Bessemer Group Inc., California Public Employees Retirement System, Goldman Sachs Group Inc., Nuveen Asset Management LLC, Two Sigma Advisers LP, and Radnor Capital Management LLC.
View insider buying and selling activity for Spero Therapeutics
.

How do I buy shares of Spero Therapeutics?

Shares of SPRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Spero Therapeutics' stock price today?

One share of SPRO stock can currently be purchased for approximately $9.78.

How big of a company is Spero Therapeutics?

Spero Therapeutics has a market capitalization of $206.88 million and generates $18.15 million in revenue each year. The company earns $-60,920,000.00 in net income (profit) each year or ($3.35) on an earnings per share basis. Spero Therapeutics employs 57 workers across the globe.

What is Spero Therapeutics' official website?

The official website for Spero Therapeutics is sperotherapeutics.com.

How can I contact Spero Therapeutics?

Spero Therapeutics' mailing address is 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139. The company can be reached via phone at 857-242-1600 or via email at [email protected]

This page was last updated on 9/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.